GlassScriptPhysician profile
Elaina Vayntrub
NPI 1770573958
$22,232.78
in general payments reported to CMS, 2019-2025
15 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $321 · 2021: $255 · 2022: $338 · 2023: $254 · 2024: $166 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $4,025 · Travel and Lodging: $2,174 · Food and Beverage: $941 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,650.00 |
| Consulting Fee | $4,025.00 |
| Travel and Lodging | $2,174.06 |
| Food and Beverage | $940.92 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20,294.63 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $1,093.39 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Amgen INC. | $263.20 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $120.57 | 2023 | |
| Acelrx Pharmaceuticals, INC. | $110.00 | 2019 | |
| Endo Pharmaceuticals INC. | $69.94 | 2020-2022 | |
| Vivus LLC | $65.24 | 2022 | |
| Currax Pharmaceuticals LLC | $57.41 | 2021-2025 | Contrave |
| Alvogen INC | $35.30 | 2023-2025 | Teriparatide |
| Heron Therapeutics, INC. | $28.31 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $28.19 | 2019 | |
| Pfizer INC. | $20.64 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $18.45 | 2025 | Imcivree |
| Eisai INC. | $14.49 | 2019 | |
| Radius Health, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaina Vayntrub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.